Fig. 5: Design of the immunoassays. | Nature Communications

Fig. 5: Design of the immunoassays.

From: Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer’s disease biomarkers

Fig. 5

a C231D181, b C231D217 assay. T181: tau phosphorylation at threonine 181, T231: tau phosphorylation at threonine 231, T217 tau phosphorylation at threonine 217, SBG: streptavidin β-galactosidase, RGP: β-D-galactopyranoside. 2-step protocol workflow (C231D181 assay): 1) Sample incubation with a mixture of bead-conjugated capture antibody and biotinylated detector antibody, 2) Incubation with SBG; 3-step protocol workflow (C231D217 assay): 1) Sample incubation with bead-conjugated capture antibody, 2) Incubation with biotinylated detector antibody, 3) Incubation with SBG. Subsequently, immunocomplexes are resuspended in RGP (SBG substrate), resulting in generation of the fluorescent signal.

Back to article page